Advertisement

Topics

Theranexus Company Profile

06:36 EDT 26th June 2019 | BioPortfolio


News Articles [13 Associated News Articles listed on BioPortfolio]

THERANEXUS: THERANEXUS ANNOUNCES APPOINTMENT OF JEROME MARTINEZ TO ITS BOARD OF DIRECTORS

Lyon, 14 December 2018 - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction b...

THERANEXUS: THERANEXUS ANNOUNCES PRELIMINARY RESULTS OF PHASE II TRIAL OF THN102 ON NARCOLEPSY PATIENTS

Lyon, 27 February 2019 - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction b...

THERANEXUS: THERANEXUS INVITED TO JOIN IN THE HEALTHTECH INVESTOR DAYS (HTID) 24 and 25 JUNE IN PARIS

Lyon, 20 June 2019 - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction betwe...

THERANEXUS: THERANEXUS ANNOUNCES ISSUANCE OF CHINESE PATENT COVERING ITS DRUG CANDIDATE THN102

Lyon, 24 April 2019 - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction betw...

THERANEXUS: THERANEXUS REPORTS CASH POSITION AS OF 31 DECEMBER 2018 AND PROVIDES UPDATE ON CURRENT STATUS OF ACTIVITIES

TOTAL AVAILABLE FUNDS ON 31 DECEMBER 2018: €15.2M FOUR ONGOING CLINICAL TRIALS ON THREE DRUG CANDIDATES UPDATE ON NEW ACTIVE AGENT SCREENING PLATFORM NEUROLEAD Lyon, 13 February 2019 - Theranexus,.....

Theranexus: THERANEXUS Set to Receive €6.2 million in Funding from the French Investments for the Future Program, Managed by Bpifrance, for the Development of Neurolead, its New Lead Generation Platform Targeting Neuro-glia Interactions

LYON, FRANCE / ACCESSWIRE / January 29, 2019 / Theranexus (Euronext Paris: ALTHX) has been awarded a €6.2 million funding package through the Investments for the Future program (PIA), managed by Bp....

THERANEXUS: THERANEXUS set to receive EUR 6.2 million in funding from the French Investments for the Future program, managed by Bpifrance, for the development of Neurolead, its new lead generation platform targeting neuro-glia interactions

Lyon, 29 January 2019 - Theranexus (ALTHX) has been awarded a €6.2 million funding package through the Investments for the Future program (PIA), managed by Bpifrance (Structuring Research and Deve.....

THERANEXUS: THERANEXUS ANNOUNCES RESEARCH COLLABORATION WITH IRISA* USING ARTIFICIAL INTELLIGENCE TECHNOLOGIES TO ENHANCE THERAPEUTIC TARGETING OF NEUROGLIAL INTERACTIONS

The collaboration, in line with the new Neurolead platform, aims to enhance the selection and qualification capabilities of new therapeutic assets targeting neuroglial interactions. Lyon, 9th Apri...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

More Information about "Theranexus" on BioPortfolio

We have published hundreds of Theranexus news stories on BioPortfolio along with dozens of Theranexus Clinical Trials and PubMed Articles about Theranexus for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Theranexus Companies in our database. You can also find out about relevant Theranexus Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record